Qizheng Tibetan Medicine saw a 15.2% increase in revenue last year and released its 10th Social Responsibility Report during the same period.

　　Recently, Qizheng Tibetan Medicine disclosed its 2018 annual report. During the reporting period, the company’s sales revenue reached 1.213 billion yuan, representing a year-on-year increase of 15.2%; net profit amounted to 319 million yuan, up 6% from the previous year; earnings per share were 0.79 yuan; and total tax payments totaled 215 million yuan, of which 188 million yuan was paid in Tibet.

　　Introduction to Qizheng Tibetan Medicine: As of the end of 2018, one product of the company had been included in the National Essential Medicines List; 17 products were listed in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List; 53 products were included in local provincial medical insurance lists; 26 products were included in local essential medicine lists; 41 products were included in the Urban and Rural Resident Medical Insurance or New Cooperative Medical Scheme lists; 9 products were included in local low-price drug lists; and 2 products were included in the National Emergency (Rescue) Medicines List.

　　Qizheng Tibetan Medicine stated that in 2019, the company will continue to strengthen its academic leadership and professional-driven approach to ensure sustainable business development. With a focus on bolstering its core pain-relief product line—centered around its pain-relief plaster—Qizheng will collaborate with Bai Mai Ointment, Qing Peng Ointment, and Ruyi Zhenbao Tablets to create an integrated brand strategy for pain management and explore digital marketing models for prescription drugs. The company will also emphasize expanding into urban markets, deepening distribution channels, building grassroots academic marketing platforms, and establishing benchmark hospitals in academic excellence. Furthermore, Qizheng plans to expand its product offerings in the fields of women’s and children’s health, promote the “Shan Wei” family of digestive system products and the “Hu Fei” family of respiratory system products, integrate Tibetan medicine’s distinctive treatment protocols for key disease categories, and provide customers with comprehensive diagnostic and therapeutic solutions, thereby driving the joint growth of all product lines within the company.

　　The company also released the “Qizheng Tibetan Medicine 2018 Corporate Social Responsibility Report” at the same time. This marks the tenth consecutive year that Qizheng Tibetan Medicine has published a corporate social responsibility report.

　　As the first domestic company to list Tibetan medicine on the stock market, Qizheng Tibetan Medicine’s core business encompasses the research and development, production, and sales of Tibetan medicines. The company has 15 wholly-owned and controlling subsidiaries, including GMP-certified pharmaceutical factories and GSP-compliant marketing companies, and employs a total of 1,934 people. Guided by the mission of “promoting wisdom and caring for health,” the company integrates the time-honored essence of traditional Tibetan medicine—spanning over two millennia—with cutting-edge technologies and materials. By leveraging scientific and technological means, it addresses the challenges of modernizing traditional Tibetan medicine, continuously innovating dosage forms to better meet the needs of contemporary consumers and earning widespread market recognition.

　　Qizheng Tibetan Medicine adheres to the corporate values of “doing good and benefiting others, pursuing integrity and righteous conduct,” and takes “customer first” as its guiding principle. The company strictly complies with all requirements of GMP and GSP, ensuring product quality and enabling consumers to shop with peace of mind. Leveraging modern medical research methods, the company continuously explores and deepens the unique clinical value of Tibetan medicine, providing guidance for contemporary clinical drug use. By integrating Tibetan medicine’s strengths in specific disease categories and specialized treatment protocols, the company has become a “personal assistant” for consumers and a “medical service assistant” for primary-care physicians, offering doctors and patients an expanded range of products and treatment options.

　　In terms of technological innovation, Qizheng Tibetan Medicine is focusing on building green and smart factories, promoting green and intelligent manufacturing, and striving to establish an efficient, clean, low-carbon, and circular green manufacturing system that will lead the modernization of the Tibetan medicine industry. In 2018, the renovation and expansion project of the Linzhi Manufacturing Center, a subsidiary of Qizheng Tibetan Medicine, was carried out as scheduled, with the goal of transforming the center into an intelligent factory for externally applied Tibetan medicine preparations, integrating automated production control, dispatching, management, and business decision-making. In the future, the Linzhi Manufacturing Center will serve as a model for the digital and intelligent transformation and upgrading of Tibetan medicine enterprises in Tibet.

　　As a traditional ethnic medicine enterprise deeply rooted in the Tibetan region, Qizheng Tibetan Medicine places particular emphasis on cultivating talent in ethnic areas, promoting the sustainable use of natural resources and the environment, and safeguarding the biodiversity of the Qinghai-Tibet Plateau. While pursuing its own development, Qizheng Tibetan Medicine has also been committed for many years to charitable and public welfare initiatives. As of the end of 2018, Qizheng Tibetan Medicine had cumulatively invested over 100 million yuan in social welfare projects—including medical care, education, and poverty alleviation—in Tibetan areas and western China.

　　Reporting media: Securities Daily

　　Report link: http://www.zqrb.cn/gscy/gongsi/2019-04-23/A1556017544896.html